Get the Stockscreener App
18.66
0.96%
-0.18
Oculis Holding Ag stock is traded at $18.66, with a volume of 20,604.
It is down -0.96% in the last 24 hours and down -13.61% over the past month.
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
See More
Previous Close:
$18.84
Open:
$18.8
24h Volume:
20,604
Relative Volume:
0.29
Market Cap:
$905.76M
Revenue:
-
Net Income/Loss:
$-75.28M
P/E Ratio:
-9.3501
EPS:
-1.9957
Net Cash Flow:
$-57.45M
1W Performance:
-0.27%
1M Performance:
-13.61%
6M Performance:
+56.28%
1Y Performance:
+61.98%
1-Day Range:
$18.69
$19.26
1-Week Range:
$17.49
$19.26
52-Week Range:
$10.55
$23.08
Oculis Holding Ag Stock (OCS) Company Profile
Compare OCS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCS
Oculis Holding Ag
|
18.69 | 905.76M | 0 | -75.28M | -57.45M | -1.9957 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.90 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.33 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
579.80 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.95 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
250.04 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-23 | Initiated | Chardan Capital Markets | Buy |
| Oct-05-23 | Initiated | Stifel | Buy |
| Jun-14-23 | Initiated | BofA Securities | Buy |
| Jun-12-23 | Initiated | H.C. Wainwright | Buy |
| Jun-08-23 | Initiated | Robert W. Baird | Outperform |
| May-10-23 | Initiated | Pareto | Buy |
| Apr-28-23 | Initiated | Wedbush | Outperform |
View All
Oculis Holding Ag Stock (OCS) Latest News
H.C. Wainwright cuts Oculis stock target to $29, keeps Buy rating By Investing.com - Investing.com South Africa
Oculis price target raised to $32 from $31 at BofA - TipRanks
Oculis Holding AG Faces Heightened Cybersecurity Risks Amid Geopolitical Tensions - TipRanks
Oculis (NASDAQ:OCS) Shares Gap Down Following Weak Earnings - Defense World
Oculis Holding AG Reports 2024 Financial Results - TipRanks
Oculis Reports 2024 Fourth Quarter Net Loss, Completes $100 Million Equity Financing to Support Pipeline - Vision Monday
Stifel maintains Buy on Oculis shares, price target at $35 By Investing.com - Investing.com South Africa
Oculis Holding AG reports results for the quarter ended December 31Earnings Summary - TradingView
Oculis Holding AG (OCS) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Oculis Holding AG Reports 2024 Financial Results and Clinical Progress - TipRanks
Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update - The Manila Times
Oculis (OCS) Projected to Post Quarterly Earnings on Monday - Defense World
(OCSAW) On The My Stocks Page - Stock Traders Daily
Oculis to Present at Upcoming March Investor Conference - The Manila Times
(OCS) Investment Report - Stock Traders Daily
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - Marketscreener.com
(OCS) On The My Stocks Page - Stock Traders Daily
Oculis Holding AG (NASDAQ:OCS) Short Interest Down 68.6% in January - MarketBeat
Oculis (NASDAQ:OCS) Shares Down 7.2%Should You Sell? - MarketBeat
Oculis Holding AG Prices $100 Million Oversubscribed Share Offering - TipRanks
Oculis Holding Prices Offering of 5 Million Shares -February 14, 2025 at 04:36 am EST - Marketscreener.com
Biopharmaceutical Company Oculis Seeks $100 Million from Share Sale -February 14, 2025 at 12:56 am EST - Marketscreener.com
Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares - The Manila Times
Major Funding Breakthrough: Oculis Secures $100M for Revolutionary Eye Treatment Development - StockTitan
Oculis Raises Massive $100M War Chest: Major Pipeline Expansion for Revolutionary Eye Treatment - StockTitan
Oculis greinir frá umframeftirspurn og öðrum niðurstöðum 100 milljón USD útboðs á almennum hlutum - GlobeNewswire Inc.
Institutions along with retail investors who hold considerable shares inOculis Holding AG (NASDAQ:OCS) come under pressure; lose 8.9% of holdings value - Simply Wall St
(OCS) Trading Report - Stock Traders Daily
abrdn plc Buys 188,871 Shares of Oculis Holding AG (NASDAQ:OCS) - MarketBeat
Oculis (NASDAQ:OCS) Trading Down 0.2%Time to Sell? - MarketBeat
Insider Alert: Oculis Leadership Team Hits Major Share Vesting Milestone - StockTitan
Oculis (NASDAQ:OCS) Shares Down 0.2% – Time to Sell? - Defense World
Oculis updates share capital for its existing at-the-market offering program - The Manila Times
Oculis Secures Financial Flexibility: Strategic $100M ATM Program Backed by 2.5M Fresh Shares - StockTitan
Here's Why Momentum in Oculis Holding AG (OCS) Should Keep going - MSN
Trend Tracker for (OCS) - Stock Traders Daily
Oculis Announces Significant Voting Rights Changes Following Íslandsbanki Activity - StockTitan
Oculis Is An Interesting Growth Bet On Non-Invasive Eye Care (NASDAQ:OCS) - Seeking Alpha
Oculis Announces Major Voting Rights Changes Involving Íslandsbanki in Switzerland - StockTitan
Oculis Publishes Notification of Major Changes in Voting Rights - GlobeNewswire
(OCS) Proactive Strategies - Stock Traders Daily
Here's What Could Help Oculis Holding AG (OCS) Maintain Its Recent Price Strength - MSN
Oculis (NASDAQ:OCS) Reaches New 12-Month HighTime to Buy? - MarketBeat
Oculis (NASDAQ:OCS) Shares Gap Up – Here’s Why - Defense World
Head to Head Comparison: Oculis (NASDAQ:OCS) vs. Immunome (NASDAQ:IMNM) - Defense World
Accure Therapeutics partner Oculis reached positive phase 2 results for lead neuroprotective therapy - MENAFN.COM
Oculis (NASDAQ:OCS) Shares Gap UpWhat's Next? - MarketBeat
Oculis Holding Ag Stock (OCS) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):